NeuroSense Therapeutics is a clinical stage Biotech company dedicated to providing a novel, disease-modifying drug for ALS.

We are currently conducting two clinical trials in Israel and the United States, and are raising capital in order to prepare for a robust Phase II/III clinical trial in several sites in the United States, Canada and Israel.

We invite you to take part in our program and accelerate the clinical development towards a cure for ALS patients.

You are welcome to contact us at: info@neurosense-tx.com